T
he prognosis for patients with malignant gliomas has improved minimally during the past 30 years, despite advances in surgical, radiotherapeutic, and chemotherapeutic treatment modalities (10, 18, 23, 35) . The poor results and significant morbidity associated with conventional treatment approaches for these tumors have provided an impetus for evaluating alternative therapeutic modalities that are more effective and capable of selectively targeting tumor cells. A significant focus of these research efforts has involved attempts to use cellular and humoral immune mechanisms to directly and specifically kill tumor cells (5, 17, 25, 26, 32, 39) . The brain, and particularly brain tumors, however, present many challenges to successful immunotherapy that in part have accounted for the disappointing results of early immunotherapeutic approaches for patients with these tumors (11, 14, 20, 21) .
Recent studies in other tumor systems have helped to define the parameters that are critical for the initiation of a productive immune response (13, 19, 28, 37) . A central element in this process involves the presentation of tumor antigens in the appropriate context by so-called antigenpresenting cells to T-lymphocytes, which can then infiltrate and potentially attack the tumor. Dendritic cells (DCs), which are the most potent antigen-presenting cells, have therefore emerged as a promising component of vaccination strategies designed to promote a host response against a tumor target. A variety of strategies have been used for antigen delivery to DCs, including "pulsing" with tumor cell lysate/extract, tumor deoxyribonucleic acid and ribonucleic acid, and tumorspecific peptides (4, 17, 19, 26) . One approach that has seemed particularly promising in recent studies with various solid tumor models has involved the delivery of tumor cell apoptotic bodies, which provide a readily available source of tumor antigens for uptake, processing, and presentation by DCs (2, 3, 8) . However, the applicability of this approach for central nervous system tumors has not been reported.
Given the challenges involved in initiating a productive immune response against a central nervous system tumor target, we explored the applicability of a vaccination strategy that used glioma apoptotic body-pulsed DCs for inhibiting the growth of established intracranial tumors in a syngeneic rodent glioma model system. Apoptosis was induced by pretreating rat 9L gliosarcoma cells with 7-hydroxystaurosporine (UCN-01), a selective protein kinase C inhibitor, which was demonstrated in previous studies to induce programmed cell death in a reproducible, exposure time-dependent fashion (6). In the current study, we observed that apoptosis induction facilitated glioma antigen uptake by DCs and, more important, that these apoptotic body-pulsed DCs were capable of delaying and in many cases preventing the growth of intracranial gliomas.
MATERIALS AND METHODS

Cell culture
Rat 9L gliosarcoma cells were maintained in minimal essential medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin G, 100 U/ml streptomycin sulfate, and 2.5% l-glutamine. Cells were cultured from passages 25 to 35 in 75-cm 2 flasks. Culture media were changed twice per week. Cells were incubated at 37°C in 5% CO 2 and subcultured weekly. For implantation, cells were washed in Hanks' balanced salt solution (HBSS), detached in 1 ml 0.25% trypsin, collected by centrifugation (2000 ϫ g for 7 min), and resuspended in HBSS.
Bone marrow-derived DCs were harvested from the femurs and the tibias of female Fischer 344 rats (National Cancer Institute, Charles River Laboratories, Frederick, MD). Cells were cultured as described previously with slight modification (9, 36) . Before plating in 75-cm 2 flasks at a density of 4 ϫ 10 6 cells/ml, red blood cells were depleted using lysis buffer. Culture medium was composed of RPMI 1640, 2 mmol/L l-glutamine, 50 g/ml gentamicin, 10 mmol/L N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, 0.5 mmol/L N-methyl arginine, 10% fetal bovine serum, 0.1 mmol/L nonessential amino acids, 0.05 mmol/L 2-mercaptoethanol, supplemented with recombinant murine granulocyte-macrophage colony-stimulating factor (1000 U/ml), interleukin-4 (1000 U/ml), and flt-3 ligand (75 ng/ml). Flt-3 ligand has been observed by our group (CS BrissetteStorkus, JC Kettel, T Witham, KM Giezeman-Smits, LA Villa, WH Chambers, submitted for publication) and by others (7, 15, 40) to enhance DC recovery in culture. Cytokines were replenished by exchanging half of the media every 2 days. Day 8 DCs were harvested from flasks by gentle pipetting of the nonadherent and loosely adherent cells. Rat DC phenotype was confirmed by staining cells with antibodies directed against the major histocompatibility complex class II antigen (OX-6), a rat myeloid cell marker, OX-42, and an integrin, OX-62, followed by twocolor flow cytometry.
Assay for physical interaction between DCs and UCN-01-treated apoptotic 9L glioma cells
To examine the effect of tumor cell apoptosis on the uptake of glioma antigens by DCs, 9L cells were treated in vitro with 200 ng/ml of UCN-01 for 72 hours. At this point, approximately 50% of the glioma cells exhibited evidence of apoptosis as assessed by terminal deoxynucleotide transferasemediated deoxyuridine triphosphate nick end-labeling assay (34) , as compared with less than 5% of vehicle-treated cells, in agreement with our previously reported results (6) . The glioma cells were then washed and labeled with PKH26 (16), a membrane-incorporated fluorescent marker. Syngeneic bone marrow-derived DCs were then admixed with UCN-01-treated 9L cells using a DC-to-tumor ratio of 5:1, and association between these two cell populations was evaluated immediately after mixing the cells and after in vitro co-culture at 37°C for 24 hours. Two-color flow cytometry was used to identify uptake and/or association of the PKH26-labeled glioma cells by the DCs, which were labeled by use of fluorescein isothiocyanate-conjugated OX-6 (labels major histocompatibility complex class II).
Assessment of vaccination strategies in an intracranial 9L gliosarcoma model
The efficacy of DCs co-cultured with UCN-01-treated (apoptotic) 9L glioma cells as a vaccine strategy was assessed in an intracranial 9L model using a series of experimental conditions. The Animal Research and Care Committee of the Children's Hospital of Pittsburgh approved all animal studies. In these experiments, 4-to 6-week-old female Fischer 344 rats (Charles River Laboratories) were used.
For intracranial tumor injection, rats were anesthetized with ketamine (100 mg/kg) and acepromazine (0.02 mg/kg) and immobilized in a stereotactic frame. Via a small right paramedian scalp incision, an opening was made in the frontal bone by use of an 18-gauge needle tip. Stereotactic injection of 1 ϫ 10 4 9L cells in a volume of 3 l HBSS was directed into the right frontal lobe by use of a Hamilton syringe at a depth of 3 mm. For subsequent subcutaneous vaccinations, cells were suspended in 100 l of a 1:1 mixture of phosphatebuffered saline/Matrigel (BD Biosciences, San Jose, CA) and injected into the right or the left flank. Details of the vaccination approaches used are described below.
The animals harboring intracranial tumors were examined daily for evidence of neurological symptoms, and their weights were obtained weekly. The animals were killed when they manifested hemiparesis or weight loss of at least 20% of their body weight. Brain specimens were examined histologically to confirm that the cause of death was tumor growth in each case. The animals harboring subcutaneous vaccine site tumors that were larger than 1.5 cm in maximal diameter were killed. Survival curves were compared using a log-rank test.
For the production of apoptotic glioma cells to be used in the in vivo studies described below, 9L cells were treated with 200 ng/ml UCN-01 in vitro for 72 hours in initial studies or 300 ng/ml UCN-01 for 96 hours in subsequent experiments. Control 9L cells were treated with vehicle alone. Cells were then harvested and washed before co-culture with DCs. Three general aims were pursued in the in vivo studies, as described below.
Assessment of the therapeutic activity of DCs cocultured with apoptotic glioma cells
Our initial studies were designed to determine whether vaccination with DCs co-cultured with apoptotic 9L cells improved survival as compared with administration of apoptotic 9L cells alone or with DCs co-cultured with nonapoptotic (i.e., vehicle-treated) 9L cells, and whether these groups had improved survival as compared with animals that received unmodified 9L. On Day 0, rats (n ϭ 24) underwent intracranial implantation of 1 ϫ 10 4 9L cells. Immediately thereafter, the animals were treated with subcutaneous injections of the following: 1 ϫ 10 5 9L cells (n ϭ 6); UCN-01-treated (apoptotic) 9L cells (1 ϫ 10 5 ) (n ϭ 6); DCs (5 ϫ 10 5 ) co-cultured with vehicle-treated (nonapoptotic) 9L (1 ϫ 10 5 ) (n ϭ 6); or DCs (5 ϫ 10 5 ) co-cultured with UCN-01-treated 9L (1 ϫ 10 5 ) (n ϭ 6). The animals that received DCs co-cultured with vehicletreated 9L or UCN-01-treated 9L underwent repeat subcutaneous injections with co-cultured cells 1 and 4 days after tumor implantation. At these time points, the other animals received additional injections of vehicle only.
Determination of whether co-culture is essential for therapeutic efficacy
On the basis of our initial results, we next questioned whether co-culture of DCs with apoptotic 9L cells was essential for prolonging survival or whether delivery of apoptotic 9L cells and DCs at separate sites would generate comparable results. On Day 0, the animals (n ϭ 14) underwent intracranial implantation of 1 ϫ 10 4 9L cells. Additional Day 0 treatment included the following: subcutaneous injection of HBSS (n ϭ 4); subcutaneous injection of 1 ϫ 10 6 DCs and 2 ϫ 10 5 UCN-01-treated 9L cells at separate sites (n ϭ 5); or subcutaneous injection of 1 ϫ 10 6 DCs co-cultured with 2 ϫ 10 5 UCN-01-treated 9L cells (n ϭ 5). The injections were repeated 1 and 4 days after tumor implantation.
Evaluation of intensification of the vaccination schedule
Last, we examined whether intensification of the vaccination schedule could achieve long-term survival even in the setting of preestablished intracranial tumor. The animals (n ϭ 32) underwent intracranial injection of 1 ϫ 10 4 9L cells on Day 0. Treatment groups included the following: "control" animals (n ϭ 8) that received subcutaneous injection of HBSS; 2) "DC-only" animals (n ϭ 8) that received subcutaneous injection of 1 ϫ 10 6 DCs; "separate injection" animals (n ϭ 8) that received subcutaneous injections of 1 ϫ 10 6 DCs and 2 ϫ 10 
RESULTS
Assay of physical interaction between DCs and UCN-01-treated apoptotic 9L glioma cells
Two-color flow cytometry of OX-6/fluorescein isothiocyanate (major histocompatibility complex class II)-labeled DCs and PKH26-labeled 9L cells is shown in Figure 1 
Assessment of vaccination strategies in an intracranial 9L gliosarcoma model
Assessment of the therapeutic activity of DCs cocultured with apoptotic glioma cells
The initial studies were designed to assess the efficacy of vaccination with apoptotic 9L cells co-cultured with DCs in animals harboring intracranial tumors. As shown in Figure 2 , a statistically significant improvement in survival was observed for animals that had been vaccinated with DCs cocultured with UCN-01-treated (i.e., apoptotic) 9L cells relative to control groups that had been vaccinated with vehicletreated (i.e., nonapoptotic) 9L cells alone, vehicle-treated 9L cells co-cultured with DCs, or UCN-01-treated 9L cells alone (P ϭ 0.004, 0.004, and 0.01, respectively). However, no longterm (i.e., Ͼ90 d) survivors were observed in any of the groups. Not unexpectedly, the animals that had received vehicle-treated 9L cells (i.e., live, untreated tumor cells) developed enlarging tumors at the subcutaneous "vaccination" site. Small vaccine-site tumors also were noted in three of six animals immunized with DCs co-cultured with UCN-01-treated 9L and in all six animals immunized with UCN-01-treated 9L cells alone. Given that vaccine site tumors were observed in these animals, we increased the concentration of UCN-01 to 300 ng/ml and the incubation time to 96 hours in subsequent experiments.
Determination whether co-culture is essential for therapeutic efficacy
On the basis of the initial results, which demonstrated prolongation of survival in animals that received UCN-01-treated 9L cells co-cultured with DCs, we examined whether co-administration of DCs and apoptotic glioma cells was essential to provide an antitumor effect. Therefore, these studies included an additional control group of animals that received vaccinations with DCs and apoptotic 9L cells at separate sites. Survival curves are shown in Figure 3 . The animals that received DCs co-cultured with UCN-01-treated 9L had significantly longer survival than either HBSS-treated controls or animals that received vaccinations with UCN-01-treated 9L cells and DCs at separate sites (P ϭ 0.003 and 0.04, respectively). A more modest but statistically significant improvement in survival relative to controls also was observed in animals that had received vaccination with DCs and UCN-01-treated 9L at separate injection sites (P ϭ 0.03). There were no long-term survivors, and no subcutaneous tumors were observed at any of the vaccination sites.
Evaluation of intensification of the vaccination schedule
In an attempt to determine whether modification of the vaccination procedure could produce long-term survivors and possible cure of previously established intracranial 9L tumors, a more intensive, sequential vaccination strategy was used. This approach demonstrated that the animals that had received vaccination beginning on posttumor implantation Day 3 with DCs co-cultured with UCN-01-treated 9L had significantly longer survival times than did the HBSS-treated controls (P Ͻ 0.0001), the animals treated with DCs only (P Ͻ 0.0001), and the animals treated with injections of UCN-01-treated 9L cells and DCs at separate sites (P ϭ 0.01). Longterm survival (Ͼ90 d) was observed in 6 (75%) of 8 co-culturetreated animals versus 1 (12.5%) of 8 animals that had received apoptotic 9L cells and DCs at separate sites, and 0 (0%) of 16 controls (Fig. 4) . Three of four long-term survivors that were rechallenged with intracranial 9L in the opposite hemisphere also survived over the long term (Ͼ90 d).
With the sequential injection strategy, some animals developed subcutaneous tumors at the vaccine site. In animals that had received vaccination with DCs co-cultured with UCN-01-treated 9L, a small mass was observed at the vaccine site in five of eight cases. In each case, the maximum diameter did not exceed 0.5 cm, and complete regression was observed in all cases by Day 65. In contrast, the animals that had been vaccinated with separate injections of DCs and UCN-01-treated 9L developed a mass at the vaccine site that was confirmed to be tumor in all eight cases and that demonstrated steady growth in each case.
DISCUSSION
DCs are endogenous antigen-presenting cells that act as initiators and modulators of an immune response. Novel antitumor therapy in experimental models has recently focused on the use of "pulsed" DC vaccinations. In these models, DCs may be loaded in vitro with tumor-specific antigenic peptides, tumor cell extract or lysate, deoxyribonucleic acid-or ribonucleic acid-encoding tumor antigens, and apoptotic tumor cells (4, 8, 17, 19, 26) . The rationale for the use of these methods of DC loading rather than simple co-culture with live tumor cells is that these cells generally are poorly immunogenic, unless they are genetically modified by transfection (1, 25, 27, 30, 38) , possibly because they secrete a variety of immunologically suppressive substances such as Fas ligand and transforming growth factor ␤, which may impair DC activity and impede the efficacy of an induced immune response (29, 31, 33) . In contrast, DCs pulsed with tumor antigens have been demonstrated to induce a potent antitumor T cell response in host animals (4, 19, 42) . Furthermore, potent central nervous system immunity has been demonstrated with DCs pulsed with tumor antigens (26) . However, the lack of universal tumorspecific antigens in human malignant gliomas is a limitation of this approach. Because a potent T cell response also has been reported with the use of apoptotic cell antigens that cross-presented by DCs (2, 3) , we investigated the applicability of such an apoptotic tumor-based DC vaccination strategy as a therapeutic approach in a rat glioma model.
We applied a novel technique for the induction of tumor cell apoptosis using signal transduction inhibition. In preliminary studies, we demonstrated that UCN-01, a protein kinase C and cyclin-dependent kinase inhibitor, induced timedependent apoptosis in glioma cell lines with a peak in the apoptotic index after 3 to 4 days of continuous drug exposure at a concentration of 200 to 300 ng/ml, depending on the cell line (6) . Results from the current study using a terminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling assay confirmed that tumor apoptosis was achieved in rat 9L gliosarcoma cells after incubation with 200 or 300 ng/ml of UCN-01 for 72 or 96 hours. Although a high percentage (Ͼ50%) of cells were rendered apoptotic with the lower-dose 3-day treatment regimen, complete tumor cell killing was not achieved, which is consistent with the observation that enlarging subcutaneous tumors were noted at the vaccination site in some of the animals that had received cells treated with this dose. To further diminish the percentage of viable cells, the concentration of UCN-01 was increased in subsequent experiments to 300 ng/ml, and the in vitro incubation period with 9L was increased to 96 hours. In these studies, enlarging vaccine site tumors did not develop in the animals that had received the apoptotic body-pulsed DC vaccine. Although some of these animals transiently developed a small (Ͻ5 mm) mass at the vaccine site, complete regression was noted in each case, suggesting that this manifestation reflected a local inflammatory response that eradicated any remaining viable tumor cells or tumor cell components at the vaccine site. No subsequent tumor growth was observed during the entire follow-up period, which extended past 180 days. These results were confirmed in a subsequent cohort of animals, in which no enlarging vaccine site tumors were detected after apoptotic glioma cell-pulsed DC vaccination, despite more than 120 days of survival.
A recent report demonstrated that the efficacy of a DCtumor cell vaccine in an experimental model for melanoma was dependent on a physical interaction between tumor cells and DCs (8) . The results of the current study support this view. We have demonstrated through two-color flow cytometry that UCN-01-treated 9L cells and DCs form a physical interaction after in vitro co-culture for 24 hours. The majority of cells stained for both the PKH26-labeled component (9L cells) and the fluorescein isothiocyanate-labeled OX-6 ϩ (DC) component. In contrast, UCN-01-treated 9L cells and DCs that were mixed immediately before flow cytometry exhibited separate populations of staining, indicating that the development of a physical interaction between tumor cells and DCs requires a period of co-culture. Although these flow cytometry data do not confirm the type of physical interaction between the apoptotic cells and the DCs (e.g., engulfment versus other physical association, such as attachment), confocal microscopic studies indicated that the interaction was one of engulfment of the apoptotic glioma cells by the DCs (data not shown). Presumably, these apoptotic glioma cell-pulsed DCs were able to process and present relevant antigens to the host immune system that not only prevented growth of remaining viable glioma cells at the subcutaneous vaccine site but also led to regression of a previously established tumor at a distant intracranial site.
A vaccination strategy using these glioma apoptotic bodypulsed DCs demonstrated substantial efficacy in a 9L rat intracranial tumor model. Although some prolongation of survival was observed after administration of apoptotic glioma cells that had not been co-cultured with DCs, this effect was significantly less potent than that observed with DCs that had been cocultured with apoptotic glioma cells. The modest efficacy achieved with administration of apoptotic glioma cells alone presumably reflected some level of endogenous antigen uptake and presentation by DCs residing in the vaccine site microenvironment. These cells would perform the same role as the cocultured DCs, although perhaps less efficiently, because our ex vivo co-culture approach permitted the isolation of large numbers of DCs that had been stimulated appropriately by cytokine administration before their priming with apoptotic glioma cells. Thus, animal survival in the apoptotic cell/DC co-culture group was significantly better after both single and multiple courses of vaccination than it was in the group that received co-cultured DCs and unmodified (i.e., vehicle-treated) glioma cells or the group that received apoptotic tumor cells alone. Six (75%) of eight animals exhibited long-term survival with the sequential vaccination strategy consisting of DCs co-injected with tumor cells that were induced to undergo apoptosis by UCN-01 pretreatment. A memory response was also achieved in the majority of these long-term survivors, because three (75%) of four animals that were rechallenged by intracranial injection also survived over the long term. The exact antitumor mechanism of this vaccination approach is the focus of future investigations, but it is likely to be the result of a cell-mediated immune response, as has been demonstrated in other glioma vaccination models. Our previous studies, in which we used cytokine gene-transduced glioma cells as a vaccination strategy, demonstrated abundant infiltration of the primary tumor site by CD4 ϩ and CD8 ϩ lymphocytes in the setting of tumor rejection (22, (25) (26) (27) 41) and confirmed the presence of a tumor-specific immune response that could be transferred adoptively to induce an antitumor response in naïve animals (12, 41) .
Because of the efficacy and applicability of DC-based vaccination approaches, clinical implementation of apoptotic body-pulsed DCs as a vaccination strategy for high-grade gliomas has been developed as a Phase I clinical trial at our center. Investigators in other ongoing studies are examining which glioma-expressed antigens are responsible for mediating an effective antitumor immune response (24) .
With the advent of molecular biological and gene therapy techniques, there has been a considerable renewal of interest in investigating the potential of immunotherapy in the treatment of patients with malignant brain tumors. One of the reasons for the failure of previous immunotherapy trials was the limitation imposed by the brain tumor itself in its failure to present antigens to the immune system effectively and thus stimulate a potent immune response. A second limitation was the physician's inability to deliver immunotherapy to the brain tumor effectively and sustain an immune response in the central nervous system. DCs have recently emerged as perhaps the immunologist's "savior." These cells are known to be potent antigen-presenting cells and thus may stimulate a sufficient immune response to be valuable in the treatment of intracerebral tumors.
The goal of the present study was to find a way to augment the immune response against a glioma by using stimulated DCs. The hypothesis of the study is that introducing apoptosis in a glioma might result in a stronger antitumor immune response by the DCs when the DCs are preincubated with apoptotic glioma cells before their use in a vaccine. This theory is derived from evidence suggesting that apoptotic cells provide a readily available source of tumor antigens for uptake, processing, and presentation by the DCs.
In this study, the authors explored the efficacy of subcutaneous vaccination with glioma apoptotic body-pulsed DCs in inhibiting intracerebral tumor growth in a syngeneic 9L glioma Fischer rat model. The results demonstrate that pretreatment of 9L cells with 7-hydroxystaurosporine, a stimulator of apoptosis, causes the development of apoptosis in 50% of the tumor cells as compared with only 3% of the controls. Furthermore, in animals harboring intracranial tumors, survival times were significantly longer for animals treated with a glioma apoptotic body-pulsed DC vaccine than they were in animals that received various control treatments. Surprisingly, no survival benefit was observed in animals that received DCs co-cultured with nonapoptotic 9L cells, which contradicts the results in some other studies reported in the literature. No explanation is offered for this finding. Two other problems with this article are that no systemic immune studies are reported and no histological confirmation is shown. The demonstration of immune memory in surviving animals rechallenged with tumor supports the role of the immune system, but further quantitative studies, especially in clinical trials, will be important. Another consideration for future investigation is whether other routes of delivery of DCs might be more effective. Nevertheless, this article provides more data to support the potential benefit of DCs in stimulating an antitumor response against an intracerebral tumor and their use in tumor vaccines.
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